

## Epidermolysis bullosa acquisita

Condition for which IVIg use is in exceptional circumstances only

### Specific Conditions

- Epidermolysis bullosa acquisita

### Level of Evidence

Insufficient data (Category 4a)

Intravenous immunoglobulin (IVIg) should be considered for severe cases refractory to conventional immunosuppressive therapy.

**Refer to the current product information sheet for further information.**

**The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient.**

*Generated on: 31 March 2019*